Menu
GI-ORIS used to identify drugs that should not be taken in combination.
https://news.mit.edu/2024/new-model-identifies-drugs-shouldnt-be-taken-together-0220
https://doi.org/10.1038/s41551-023-01128-9
Vivtex Enters Research Collaboration with Astellas Pharma
Cambridge, MA, USA and Zurich, Switzerland – 23rd January 2024.
Vivtex Corporation (“Vivtex” or “the Company”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, announces that it has entered a research collaboration with Astellas Pharma Inc. (“Astellas”), a global pharmaceutical company. The collaboration is focused on the evaluation of Vivtex’s unique and proprietary GI-ORIS™ (“Gut on a chip” and AI) screening and formulation platform technology to support the development of novel, oral versions of a therapeutic candidate provided by Astellas.
Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma. Over the past few years, Vivtex has worked productively with multiple leading pharma and biotech companies to apply its GI-ORIS™ platform to the challenge of improving drug oral bioavailability and thereby creating valuable new product opportunities and potential benefits to patients.”
Vivtex scientists demonstrated the ability and potential of the GI-ORIS™ platform to expedite the development of new orally available biologic drugs in a 2020 study published in Nature Biomedical Engineering (ref.1). The study showed how GI-ORIS™ can be applied to accurately model (with near-perfect predictability) the absorption of drug molecules in the small intestine, enabling Vivtex to develop novel oral formulations and delivery methodologies, previously not possible for biologic medicines based on the limitations of available technologies. Vivtex has secured a worldwide, exclusive license from MIT for this foundational technology and its applications for the development of novel oral biologic therapies.
Reference
About Vivtex Corporation
Vivtex was launched as a spin out from the labs of Robert Langer (MIT) and Giovanni Traverso (MIT, Harvard University). The company is focused on transforming the market for biologic therapies through the development of novel oral biologics including enhanced, oral versions of existing high-value biologic candidates that can only be administered by injection or infusion.
To achieve its mission, Vivtex is leveraging its proprietary and extensively validated high-throughput GI-ORIS™ (“Gut on a chip” and AI) screening and formulation platform (Nat. Biomed. Eng. 4, 544–559: 2020) through strategic co-development partnerships and R&D collaborations with biotechnology and pharmaceutical companies.
To find out more about Vivtex, please visit our website: www.vivtex.com and LinkedIn.
Contacts:
Vivtex
Maureen Deehan, CEO
MEDiSTRAVA Consulting (for international media)
Mark Swallow, Sandi Greenwood, Leila Adlam
Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases
Cambridge/Boston, MA, USA – 18th January 2024.
Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases.
The partners will leverage Vivtex’s proprietary and extensively validated GI-ORIS™ (“Gut on a chip” and AI) screening and formulation platform technology to evaluate and enhance the oral bioavailability of AI Proteins’ miniproteins designed to target and inhibit the activity of the TNF receptor 1 (TNFR1). Under the agreement, the companies will jointly conduct and share the costs of the program and will co-own any resulting data. No further financial details are disclosed.
Preventing inflammation by inhibiting TNF-alpha (tumor necrosis factor alpha) signaling is a highly validated approach and the mechanism of action of multiple approved biologic products that generate multi-billion-dollar revenues each year. There are multiple receptors for TNF-alpha and inhibition of TNFR1, which is responsible for mediating pro-inflammatory signaling activity, has the potential to be a safe and highly effective target for inhibiting this clinically important pathway. There are no FDA approved therapeutics that inhibit TNFR1, with several companies having tried and failed. AI Proteins’ de novo design process provides complete control over miniprotein properties and activity allowing them to achieve remarkable potency and novel receptor engagement to successfully drug TNFR1. With current TNF-alpha pathway inhibitors being injectables, there is a major opportunity to develop oral anti-inflammatory medicines with differentiated best-in-class safety and efficacy.
Maureen Deehan, CEO of Vivtex, commented “A key element of our new and evolved strategy is to enter collaborations with innovative companies where we can bring together our respective and cutting-edge technologies to create and co-develop novel therapeutic candidates that have the potential to address significant delivery and bioavailability challenges – in this case, an oral TNFR1 inhibitor to treat inflammatory diseases. AI Proteins’ miniprotein technology combined with our own GI-ORIS™ technology presents an opportunity to develop and bring a completely new oral anti-inflammatory medicine to patients, making this highly effective modality available to a much larger patient population.”
Noah D. Beerman, CEO of AI Proteins, added: “At AI Proteins, we are proud of the bold and dynamic science supporting our de novo miniprotein technology platform, which has the potential to make a profound impact on the development of novel medicines across multiple therapeutic spaces. To date, we have focused on designing our miniproteins to achieve ideal therapeutic characteristics and have now validated hits for over 100 targets. This collaboration aims to combine promising features of our powerful miniprotein platform and Vivtex’s transformational oral biologics platform to develop anti-inflammatory therapeutics.”
About Vivtex Corporation
Vivtex was launched as a spin out from the labs of Robert Langer (MIT) and Giovanni Traverso (MIT, Harvard University). The company is focused on transforming the market for biologic therapies through the development of novel oral biologics including enhanced, oral versions of existing high-value biologic candidates that can only be administered by injection or infusion.
To achieve its mission, Vivtex is leveraging its proprietary and extensively validated high-throughput GI-ORIS™ (“Gut on a chip” and AI) screening and formulation platform (Nat. Biomed. Eng. 4, 544–559: 2020) through strategic co-development partnerships and R&D collaborations with biotechnology and pharmaceutical companies.
To find out more about Vivtex, please visit our website: www.vivtex.com and LinkedIn.
About AI Proteins
Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications with a current focus on inflammation, metabolic diseases, and oncology. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.
For more information, please go to aiproteins.bio
Contacts:
Vivtex
Maureen Deehan, CEO
MEDiSTRAVA Consulting (for Vivtex)
Mark Swallow, Sandi Greenwood, Leila Adlam
Stern Investor Relations, Inc. (for AI Proteins)
Janhavi Mohite
Vivtex announces the promotion of Maureen Deehan to Chief Executive Officer. She joined Vivtex in December 2022 as the Chief Business & Operating Officer. Dr. Deehan is a biotechnology and pharmaceutical professional with 22 years of drug development and commercialization experience.
Vivtex CSO, Thomas von Erlach, presents at the Controlled Release Symposium entitled: Oral Delivery of Peptides, Oligonucleotides and Proteins to share Vivtex’s most recent progress in oral peptide and antisense oligonucleotide delivery.
Vivtex CSO, Thomas von Erlach, participates in a panel discussion at the 13th Annual PODD Conference in Boston, MA around oral biologics delivery and ingestible devices.
Vivtex CEO Maureen Deehan presents at the New York Venture Summit. An opportunity to showcase Vivtex and detail our journey so far.
Vivtex CSO Thomas von Erlach presents Vivtex’s most recent research findings on oral peptide delivery at the Drug Delivery & Formulation Summit in Berlin, Germany.
790 Memorial Drive Suite 300 Cambridge, MA 02139